Pulmatrix Inc.

3.67-0.0690-1.84%Vol 15.41K1Y Perf 498.69%
Dec 1st, 2022 15:46 DELAYED
BID3.65 ASK3.79
Open3.69 Previous Close3.74
Pre-Market- After-Market3.70
 - -  - -%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
172.41 
Finscreener Ranking
★★★★★     62.92
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     57.66
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     62.41
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.07 
Earnings Rating
Buy
Market Cap13.36M 
Earnings Date
9th Nov 2022
Alpha-0.06 Standard Deviation0.22
Beta1.12 

Today's Price Range

3.623.79

52W Range

3.1715.60

5 Year PE Ratio Range

-0.6000-0.7000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.57%
1 Month
5.49%
3 Months
-15.22%
6 Months
-25.59%
1 Year
498.69%
3 Years
336.97%
5 Years
-77.48%
10 Years
-

TickerPriceChg.Chg.%
PULM3.67-0.0690-1.84
AAPL148.600.57010.39
GOOG101.41-0.0450-0.04
MSFT255.570.43000.17
XOM110.86-0.4800-0.43
WFC46.94-1.0150-2.12
JNJ178.680.68000.38
FB196.640.99000.51
GE85.28-0.6900-0.80
JPM136.36-1.8249-1.32
 
ProfitabilityValueIndustryS&P 500US Markets
-
-387.30
-355.60
-4 025.40
-
RevenueValueIndustryS&P 500US Markets
4.82M
1.32
227.58
108.73
Earnings HistoryEstimateReportedSurprise %
Q03 2022-1.51-1.453.97
Q02 2022-1.51-1.369.93
Q01 2022-1.41-1.51-7.09
Q03 2021-1.40-1.80-28.57
Q02 2021-1.80-1.4022.22
Q01 2021-2.00-1.8010.00
Q04 2020-3.80-1.0073.68
Q03 2020-4.40-6.20-40.91
Earnings Per EndEstimateRevision %Trend
12/2022 QR-1.520.00-
12/2022 QR-1.520.00-
12/2022 FY-6.040.00-
12/2023 FY-6.250.00-
Next Report Date-
Estimated EPS Next Report-1.51
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume15.41K
Shares Outstanding3.64K
Shares Float3.39M
Trades Count94
Dollar Volume56.80K
Avg. Volume17.89K
Avg. Weekly Volume12.30K
Avg. Monthly Volume16.47K
Avg. Quarterly Volume24.91K

Pulmatrix Inc. (NASDAQ: PULM) stock closed at 3.7 per share at the end of the most recent trading day (a -1.84% change compared to the prior day closing price) with a volume of 15.41K shares and market capitalization of 13.36M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Pulmatrix Inc. CEO is Teofilo David Raad.

The one-year performance of Pulmatrix Inc. stock is 498.69%, while year-to-date (YTD) performance is 738.89%. PULM stock has a five-year performance of -77.48%. Its 52-week range is between 3.165 and 15.598, which gives PULM stock a 52-week price range ratio of 4.07%

Pulmatrix Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.37, a price-to-sale (PS) ratio of 2.70, a price to cashflow ratio of 3.40, a PEG ratio of 2.32, a ROA of -42.76%, a ROC of -53.31% and a ROE of -54.46%. The company’s profit margin is -%, its EBITDA margin is -355.60%, and its revenue ttm is $4.82 Million , which makes it $1.32 revenue per share.

Of the last four earnings reports from Pulmatrix Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.51 for the next earnings report. Pulmatrix Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Pulmatrix Inc. is Strong Buy (1), with a target price of $10, which is +172.41% compared to the current price. The earnings rating for Pulmatrix Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Pulmatrix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Pulmatrix Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.98, ATR14 : 0.19, CCI20 : 32.63, Chaikin Money Flow : 0.03, MACD : 0.01, Money Flow Index : 56.27, ROC : -1.58, RSI : 54.08, STOCH (14,3) : 40.53, STOCH RSI : 1.00, UO : 50.81, Williams %R : -59.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Pulmatrix Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Pulmatrix Inc.

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

CEO: Teofilo David Raad

Telephone: +1 781 357-2333

Address: 99 Hayden Avenue, Lexington 02421, MA, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

36%64%

Bearish Bullish

52%48%

Bearish Bullish

58%42%


News

Stocktwits